From the other side of the consultation, briefly.

Compounding pharmacy customer here with experience relevant to compounded supply.

I've ordered from 3 different compounding pharmacies over the past year. The quality variation is real — purity ranged from 94% to 101% of label claim based on independent Janoshik testing.

My current compounder (a 503B facility) has been consistently 98-101% purity across 6 orders. I pay $126/month vs $1,296 for brand. The savings are substantial and the product is equivalent in my experience.

Re: compounded supply — this applies whether you're using brand or compounded. The clinical principles are the same.

TrialTracker_MD said:

Compounding pharmacy customer here with experience relevant to compounded supply.

This matches mine closely enough to be worth saying so out loud.

TrialTracker_MD said:

Compounding pharmacy customer here with experience relevant to compounded supply.

503A vs 503B compounding pharmacies for compounded supply — this distinction matters enormously:

I strongly recommend 503B facilities. The FDA oversight and cGMP requirements mean more consistent product quality.

TrialTracker_MD said:

Compounding pharmacy customer here with experience relevant to compounded supply.

Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.

Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide partially resolved shortage, tirzepatide still in shortage. This directly impacts compounding availability.

One thing that is still open after TrialTracker_MD’s answer:

How would you tell the difference between that and the alternative explanation?